Analyst Price Targets — XNCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 1, 2026 11:13 am | — | Raymond James | $46.00 | $27.27 | TheFly | Xencor price target raised to $46 from $40 at Raymond James |
| August 6, 2026 12:08 pm | Steve Seedhouse | Cantor Fitzgerald | $44.00 | $20.50 | TheFly | Xencor price target raised to $44 from $43 at Cantor Fitzgerald |
| August 6, 2026 11:15 am | — | RBC Capital | $20.00 | $19.84 | TheFly | Xencor price target raised to $20 from $19 at RBC Capital |
| July 7, 2026 1:15 pm | — | Truist Financial | $27.00 | $15.13 | TheFly | Xencor price target lowered to $27 from $29 at Truist |
| December 17, 2025 10:59 am | — | Barclays | $26.00 | $16.55 | TheFly | Xencor price target raised to $26 from $23 at Barclays |
| November 24, 2025 12:17 pm | — | Truist Financial | $29.00 | $15.87 | TheFly | Xencor initiated with a Buy at Truist |
| November 6, 2025 1:57 pm | — | Cantor Fitzgerald | $42.00 | $14.75 | TheFly | Xencor price target raised to $42 from $40 at Cantor Fitzgerald |
| October 29, 2025 8:37 am | Etzer Darout | Barclays | $23.00 | $14.25 | TheFly | Xencor upgraded to Overweight from Underweight at Barclays |
| October 27, 2025 12:43 pm | Gregory Renza | RBC Capital | $18.00 | $13.83 | TheFly | Xencor price target raised to $18 from $15 at RBC Capital |
| September 16, 2025 8:49 pm | — | Barclays | $6.00 | $8.62 | TheFly | Xencor assumed with an Underweight at Barclays |
Latest News for XNCR
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.A live webcast of the presentation will be available under…
Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $23.47 and last traded at $23.12, with a volume of 962153 shares trading hands. The stock had previously closed at $23.34. Analyst Upgrades and Downgrades Several research analysts recently weighed
Dimensional Fund Advisors LP boosted its holdings in Xencor, Inc. (NASDAQ: XNCR) by 3.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,294,887 shares of the biopharmaceutical company's stock after buying an additional 45,599 shares during the quarter. Dimensional Fund Advisors
Xencor (XNCR) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.41 per share a year ago.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026. “We are excited to present XmAb819 results at ESMO this fall and for other fast-approaching key milestones across our wholly owned clinical pipeline,”…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XNCR.
U.S. House Trading
No House trades found for XNCR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.